Trial · Interventional

Status unknownNot applicableRegistry data

Liraglutide in Acute Minor Ischemic Stroke or High-risk Transient Ischemic Attack Patients With Type 2 Diabetes Mellitus

Short name LAMP

NCTNCT03948347Other idLAMP20190508

Open at ClinicalTrials.govAsk about this trial

Overview

Status: Status unknown
Phase: Not applicable
Enrollment: 1,708 participants (estimated)
Sponsor: First Affiliated Hospital of Jinan University · Other
Design: Randomized · Single masking
Countries: 1 country
China
Start: 25 Jun 2019
Primary completion: Dec 2023 (estimated)
Completion: Jun 2024 (estimated)
First posted: 13 May 2019
Last update posted: 6 Feb 2023
Conditions: Ischemic Stroke · Transient Ischemic Attack · Type 2 Diabetes Mellitus

Timeline

1 trial

Completed
Ongoing
Not yet recruiting
Stopped
Estimated dates (est.)
Results posted

2019202020212022202320242025

N/A
LAMP
NCT03948347
25 Jun 2019 to est. Jun 2024

Registry summary

Text and fields below are the sponsor's entries at ClinicalTrials.gov, shown as posted.

The purpose of this study is to assess the safety and efficacy of glucagon-like peptide-1 (GLP-1) analogue liraglutide in the treatment of acute minor stroke (National Institute of Health stroke scale, NIHSS ≤ 3) or high-risk transient ischemic attack (TIA) (ABCD2 score ≥ 4 ) patients with type 2 diabetes mellitus.

Interventions

LiraglutideDrug

Arms2

Active comparator
active
Active patients will receive liraglutide injections
No intervention
standard care/no intervention
standard care for stroke as per hospital protocol

Primary outcomes1

Outcomes the sponsor listed as primary.

Percentage of patients with the 90-day new stroke events (ischemic or hemorrhagic)
Time frame · 90 days
Registry description
Definition of ischemic stroke: An episode of neurological dysfunction caused by focal cerebral, spinal, or retinal infarction. Either of the following is considered to be an ischemic stroke: a new focal neurologic deficit lasting for less than 24 hours and not attributable to a nonischemic cause but accompanied by neuroimaging evidence of new brain infarction; sudden onset of a new focal neurologic deficit, with clinical or imaging evidence of infarction lasting 24 hours or more and not attributable to a nonischemic cause. Definition of hemorrhagic stroke: Rapidly developing clinical signs of neurological dysfunction attributable to a focal collection of blood within the brain parenchyma, ventricular system or subarachnoid space that is not caused by trauma.

Secondary outcomes(2)

Percentage of patients with the 90-day new clinical vascular events (ischemic stroke/hemorrhagic stroke/TIA/myocardial infarction/vascular death)
Time frame · 90 days
Registry description
Transient ischemic attack was defined as transient neurological deficits caused by focal brain or retinal ischemia, the clinical symptoms are generally no more than 1 hour, and the longest duration is less than 24 hours, and there is no evidence of a responsible lesion. The clinical definition of myocardial infarction denotes the presence of acute myocardial injury detected by abnormal cardiac biomarkers in the setting of evidence of acute myocardial ischemia. Vascular death was defined as death due to stroke (ischemic or hemorrhagic), systemic hemorrhage, myocardial infarction, congestive heart failure, pulmonary embolism, sudden death, or arrhythmia.
Percentage of patients with the 90-day Modified Rankin Scale (mRS) ≤ 2
Time frame · 90 days
Registry description
The modified Rankin scale is used to measure the recovery of neurological function in patients after stroke. The following questionnaire will be used to determine the mRs score: The modified Rankin scale is used to measure the recovery of neurological function in patients after stroke. The following questionnaire will be used to determine the mRs score: 0- No symptoms at all. 1. No significant disability despite symptoms; able to carry out all usual duties and activities. 2. Slight disability; unable to carry out all previous activities, but able to look after own affairs without assistance. 3. Moderate disability; requiring some help, but able to walk without assistance. 4. Moderately severe disability, unable to walk without assistance and unable to attend to own bodily needs without assistance. 5. Severe disability, bedridden, incontinent and require constant nursing care and attention. 6. Dead.

Posted results

Values are shown as posted at ClinicalTrials.gov, with their units. PepBank has not converted, pooled or compared them.

No results are posted for this trial.

A trial that is still running, or that stopped early, may post results later.

Registry data comes from ClinicalTrials.gov. Study results come from studies, not from the registry. How PepBank works

Studies2

Studies that cite this trial.

Studies with results

2 studies on this page

Indexing hint: Randomized controlled trial · 2026

4 results

Liraglutide in Acute Minor Ischemic Stroke or High-Risk Transient Ischemic Attack With Type 2 Diabetes: The LAMP Randomized Clinical Trial.

Zhu et al. 2026JAMA internal medicinecited by 10

PMID 41182740PMC12584062DOI 10.1001/jamainternmed.2025.5684PUB-41182740

CC BY4 results

Download PDF See results (4)

Indexing hint: Randomized controlled trial · 2026

6 results

Liraglutide and Recurrent Stroke by Baseline Insulin Resistance: A Post Hoc Analysis of the LAMP Trial.

Lu et al. 2026Stroke

PMID 42145088PMC13281981DOI 10.1161/strokeaha.125.056010PUB-42145088

Free to read · publisher termsCC BY-NC-ND6 results

Read at source See results (6)

Eligibility

Who could join, as posted.

Sex: All
Age: from 50 Years
Healthy volunteers: Not accepted

Inclusion and exclusion criteria, as posted

Inclusion Criteria: * Adult subjects (male or female ≥ 50 years); * Acute ischemic stroke patients (NIHSS ≤ 3 at the time of randomization) with type 2 diabetes mellitus within 24 hours of symptoms onset; * High-risk TIA patients (ABCD2 score ≥ 4 at the time of randomization) with type 2 diabetes mellitus within 24 hours of onset; * First stroke, or prior stroke without sequel (mRS score ≤ 1) and does not affect the NIHSS score; * Informed consent signed. Exclusion Criteria: * Diagnosis of hemorrhage brain disease on baseline head CT; * Iatrogenic and cardiogenic stroke; * Patients receiving thrombolysis or endovascular treatment; * Use of a GLP-1 analogue or any dipeptidyl peptidase-IV (DPP-IV) inhibitor within the 3 months prior to screening; * Family or personal history of multiple endocrine neoplasia type 2 (MEN2) or familial medullary thyroid carcinoma (FMTC); * Patients with pancreatitis or previous history of pancreatitis, inflammatory bowel disease and gastroparesis; * Pregnant, lactating women,or patients who are likely to have a pregnancy and plan to have one; * Allergic to liraglutide or excipients; * Congestive heart failure (NYHA class III-IV); * Severe liver and kidney dysfunction (AST/ALT is 3 times higher than the normal upper limit, serum creatinine is 3 times higher than the normal upper limit); * Patients with malignant tumors who are expected to have a survival period of less than three months; * Participated in other clinical trials of drugs within 3 months; * Researchers believe that patients who are not suitable for this clinical study.

PepBank is a research reference. Talk to a doctor before you use any peptide.